Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-1758 in Alzheimer's Disease
NCT07599670Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Oct 2030
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ABBV-1758 in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started May 2026; status: recruiting.
02
Drugs
ABBV-1758
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07599670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599670.